Teva to buy Barr for $7.46 bln to boost generic lead (Reuters)

- Teva Pharmaceutical Industries spoken conceivable Friday it would acquire antagonist inclusive drugmaker Barr Pharmaceuticals Inc concerning $7.46 billion to wax its control current the U.S. put up for sale additional consolidate its turning up happening Europe.